Stock Events

Almirall SA 

$9.41
17
-$0.1-1.05% Monday 13:30

Statistics

Day High
9.51
Day Low
9.51
52W High
10.18
52W Low
8.85
Volume
219
Avg. Volume
29
Mkt Cap
1.99B
P/E Ratio
0
Dividend Yield
2.09%
Dividend
0.2

Upcoming

Dividends

2.09%Dividend Yield
10Y Growth
N/A
5Y Growth
-1.46%
3Y Growth
-0.18%
1Y Growth
N/A

Earnings

13MayExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
0
0.08
0.15
0.23
Expected EPS
0
Actual EPS
0

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LBTSF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novartis
NVS
Mkt Cap206.64B
Novartis is a global healthcare company that competes with Almirall in various therapeutic areas, including dermatology, which is a key focus area for Almirall.
Pfizer
PFE
Mkt Cap147.23B
Pfizer is a large pharmaceutical company with a diverse product portfolio that includes treatments in dermatology, competing directly with Almirall's skin health products.
GSK
GSK
Mkt Cap82.38B
GlaxoSmithKline has a broad range of pharmaceutical products, including skin health solutions, making it a direct competitor to Almirall in the dermatology market.
Johnson & Johnson
JNJ
Mkt Cap356.43B
Johnson & Johnson, through its Janssen Pharmaceuticals division, offers products in dermatology, competing with Almirall in the skin care and treatment market.
Abbvie
ABBV
Mkt Cap294.65B
AbbVie has a strong presence in dermatology with its Humira product and other skin care treatments, positioning it as a competitor to Almirall.
Merck &
MRK
Mkt Cap318.6B
Merck & Co. competes with Almirall through its range of health care products, including treatments for conditions in dermatology.
AMGEN
AMGN
Mkt Cap144.25B
Amgen has a portfolio of treatments that compete with Almirall, especially in the areas of inflammatory diseases that affect the skin.
Bristol-Myers Squibb
BMY
Mkt Cap99.17B
Bristol Myers Squibb competes with Almirall in several therapeutic areas, including immunoscience and dermatology, with products that address skin conditions.
Regeneron Pharmaceuticals
REGN
Mkt Cap96.81B
Regeneron Pharmaceuticals is known for its innovative treatments in dermatology, directly competing with Almirall's dermatological products.
Astrazeneca
AZN
Mkt Cap212.54B
AstraZeneca competes with Almirall in various areas, including treatments for diseases that have dermatological implications, such as cancer and inflammatory diseases.

About

Pharmaceuticals: Major
Health Technology
Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications, as well as for cardiovascular, musculo-skeletal, respiratory, and nervous system; alimentary tract and metabolism; antiinfectives for systemic use; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Its products include Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel. Almirall, S.A. has collaboration and partnership agreements with Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
Show more...
CEO
Peter Guenter
Employees
1904
Country
ES
ISIN
ES0157097017
WKN
000A0MU8Y

Listings